| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Licoisoflavone B targets multiple enzymes and pathways. It inhibits lipid peroxidation, a process involved in oxidative stress. It inhibits the human cytochrome P450 enzymes CYP2C8 and CYP2C9. Its antimutagenic activity is important for preventing DNA damage.
|
|---|---|
| ln Vitro |
In vitro, Licoisoflavone B exhibits antimutagenic activity against MNU. It inhibits lipid peroxidation with an IC₅₀ of 2.7 μM. It inhibits CYP2C8 and CYP2C9. It also shows anti-inflammatory and antioxidant properties.
|
| ln Vivo |
In vivo, the antimutagenic and antioxidant activities of Licoisoflavone B suggest potential for cancer chemoprevention. Its inhibition of CYP2C8 and CYP2C9 could lead to drug-drug interactions. However, specific in vivo data are limited.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for Licoisoflavone B typically involve measuring its inhibition of lipid peroxidation using a model system, such as linoleic acid oxidation, and monitoring the formation of conjugated dienes or malondialdehyde (MDA). Its inhibition of CYP2C8 and CYP2C9 is measured using microsomal preparations and specific substrates.
|
| Cell Assay |
In vitro cell-based assays for Licoisoflavone B use cell lines to study its antimutagenic activity. Cells are treated with the compound and a mutagen (e.g., MNU), and the frequency of mutations is measured. Its anti-inflammatory activity is assessed in LPS-stimulated macrophages by measuring cytokine production.
|
| Animal Protocol |
In vivo animal studies for Licoisoflavone B would likely employ models of chemical carcinogenesis to study its chemopreventive effects. The compound would be administered to the animals, and the incidence of tumors would be assessed.
|
| ADME/Pharmacokinetics |
Licoisoflavone B has a molecular weight of 352.34 g/mol and a molecular formula of C₂₀H₁₆O₆. It has a purity of ≥95%. It is soluble in organic solvents. Detailed pharmacokinetic parameters have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Licoisoflavone B has not been fully characterized. As a natural compound, it is generally considered to have low toxicity. However, its inhibition of CYP2C8 and CYP2C9 suggests potential for drug-drug interactions.
|
| References | |
| Additional Infomation |
Licoisoflavone B has been reported to be found in licorice root, lupin, and other organisms with relevant data. See also: Glycyrrhiza glabra (partial); Glycyrrhiza uralensis root (partial).
Licoisoflavone B is an isoflavone from licorice root with antimutagenic, antioxidant, and anti-inflammatory properties. It inhibits lipid peroxidation and CYP2C8/CYP2C9. Not approved for clinical use. |
| Molecular Formula |
C20H16O6
|
|---|---|
| Molecular Weight |
352.33744
|
| Exact Mass |
352.094
|
| Elemental Analysis |
C, 68.18; H, 4.58; O, 27.24
|
| CAS # |
66056-30-2
|
| PubChem CID |
5481234
|
| Appearance |
White to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
588.9±50.0 °C at 760 mmHg
|
| Melting Point |
180-183℃
|
| Flash Point |
215.1±23.6 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.683
|
| LogP |
5.52
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
638
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(C=Cc2c(ccc(c2O)c3coc4cc(cc(c4c3=O)O)O)O1)C
|
| InChi Key |
KIZPADOTOCPASX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16O6/c1-20(2)6-5-12-15(26-20)4-3-11(18(12)23)13-9-25-16-8-10(21)7-14(22)17(16)19(13)24/h3-9,21-23H,1-2H3
|
| Chemical Name |
5,7-dihydroxy-3-(5-hydroxy-2,2-dimethylchromen-6-yl)chromen-4-one
|
| Synonyms |
Licoisoflavone B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8382 mL | 14.1908 mL | 28.3817 mL | |
| 5 mM | 0.5676 mL | 2.8382 mL | 5.6763 mL | |
| 10 mM | 0.2838 mL | 1.4191 mL | 2.8382 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
